Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics

For the quarter ended December 2022, Regeneron (REGN) reported revenue of $3.41 billion, down 31.1% over the same period last year. EPS came in at $12.56, compared to $23.72 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $3.17 billion, representing a surprise of +7.84%. The company delivered an EPS surprise of +29.75%, with the consensus EPS estimate being $9.68.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- Eylea (Aflibercept) - US: $1.50 billion versus the five-analyst average estimate of $1.69 billion. The reported number represents a year-over-year change of -3.3%.
  • Revenue- Libtayo - US: $110 million versus the five-analyst average estimate of $103.86 million. The reported number represents a year-over-year change of +36.1%.
  • Revenue- Eylea (Aflibercept) - ROW: $838.60 million versus the four-analyst average estimate of $864.85 million. The reported number represents a year-over-year change of -10.2%.
  • Revenue- Praluent (alirocumab) - US: $35.50 million versus $31.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -11.3% change.
  • Revenues- Net product sales: $1.70 billion versus the eight-analyst average estimate of $1.83 billion. The reported number represents a year-over-year change of -57.3%.
  • Revenues- Other Revenue: $127.70 million compared to the $57.53 million average estimate based on seven analysts. The reported number represents a change of +48.1% year over year.
  • Revenue-Collaboration: $1.59 billion versus $1.34 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +78.3% change.
  • Revenues- Collaboration revenue- Bayer: $355 million versus $349.35 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -4.7% change.
  • Revenues- Collaboration revenue- Sanofi: $836 million compared to the $712.85 million average estimate based on five analysts. The reported number represents a change of +61.4% year over year.
  • Revenues- Collaboration revenue- Roche: $396 million compared to the $245.50 million average estimate based on four analysts.
  • Revenues- Eylea (Aflibercept) - Total: $2.34 billion versus the four-analyst average estimate of $2.55 billion.
  • Revenues- Libtayo - Total: $168.80 million versus $151.25 million estimated by three analysts on average.

View all Key Company Metrics for Regeneron here>>>

Shares of Regeneron have returned +3.8% over the past month versus the Zacks S&P 500 composite's +9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.